Intellect Neurosciences Issues Letter to Shareholders
13. Februar 2013 12:32 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and...
Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody
07. Februar 2013 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences CEO Daniel Chain Provides Conference Highlights of Alzheimer's Drug Development Summit in Neurotech Insights Magazine
02. Januar 2013 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, provided conference highlights from the December 11-12...
Intellect Neurosciences CEO Daniel Chain to Discuss Vaccine Program at Alzheimer's Drug Development Summit
06. Dezember 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will discuss Intellect's vaccine program at the Alzheimer's Drug...
Intellect Neurosciences Announces New Findings Supporting its Patented ANTISENILIN Platform Technology for the Treatment of Alzheimer's Disease
28. November 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences Announces New Findings Supporting Its Tau Oligomer Selective TOC-1 Monoclonal Antibody for the Treatment of Alzheimer's Disease
06. November 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences Issues Letter to Shareholders
16. Oktober 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences Files Lawsuit Against Pharmaceutical Licensee for Non Payment of $2 Million Milestone
15. Oktober 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences and iNovacia Enter Research Service Agreement to Evaluate Lead Compounds for CONJUMAB-A Program
03. Oktober 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK and STOCKHOLM, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying...
Lonza and Intellect Neurosciences Announces Intellect's Intention to Award Production of Its Antibody Drug Conjugate, CONJUMAB-A to Lonza
27. September 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK and BASEL, Switzerland, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Lonza announced today that Intellect Neurosciences, Inc. (OTCBB:ILNS) awarded the future development and manufacture of the antibody...